Cellosaurus PSN1 (CVCL_1644)

Cell line name PSN1
Synonyms PSN-1
Accession CVCL_1644
Resource Identification Initiative To cite this cell line use: PSN1 (RRID:CVCL_1644)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Doubling time: 21 hours (PubMed=3778442); 35 hours (PubMed=25984343).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Heterozygous for KRAS p.Gly12Arg (PubMed=3778442).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Pancreatic adenocarcinoma (NCIt: C8294)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_2451 (GR-M)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12
D13S31710
D16S53911 (Cosmic-CLP)
10,11 (ATCC; PubMed=25877200)
D18S5121
D21S1129,30
D3S135815,17
D5S81811,13
D7S82010
D8S117910,14
FGA23
Penta D9,12
Penta E14,15
TH016
TPOX8,11
vWA17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=3009377; DOI=10.20772/cancersci1985.77.4_370
Yamada H., Sakamoto H., Taira M., Nishimura S., Shimosato Y., Terada M., Sugimura T.
Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes.
Jpn. J. Cancer Res. 77:370-375(1986)

PubMed=3778442; DOI=10.1016/0006-291X(86)91072-7
Yamada H., Yoshida T., Sakamoto H., Terada M., Sugimura T.
Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation.
Biochem. Biophys. Res. Commun. 140:167-173(1986)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Cancer Sci. 99:986-994(2008)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25167228; DOI=10.1038/bjc.2014.475
Hamidi H., Lu M., Chau K., Anderson L., Fejzo M., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Br. J. Cancer 111:1788-1801(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-3211
ATCC; CRM-CRL-3211
ECACC; 94060601
ICLC; HTL97008
Cell line databases/resources CLDB; cl3949
CLDB; cl3950
CCLE; PSN1_PANCREAS
CGH-DB; 182-1
CGH-DB; 9281-4
Cosmic-CLP; 910546
GDSC; 910546
LINCS_LDP; LCL-1749
Ontologies BTO; BTO:0005179
CLO; CLO_0008512
EFO; EFO_0006739
Biological sample resources BioSample; SAMN03481109
Chemistry resources ChEMBL-Cells; CHEMBL3307348
ChEMBL-Targets; CHEMBL614241
Gene expression databases GEO; GSM206537
GEO; GSM887521
GEO; GSM888603
GEO; GSM1374836
GEO; GSM1670353
Polymorphism and mutation databases Cosmic; 710867
Cosmic; 716172
Cosmic; 733176
Cosmic; 808165
Cosmic; 808504
Cosmic; 910546
Cosmic; 2434092